Share on StockTwits

Verastem (NASDAQ:VSTM)‘s stock had its “buy” rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Friday. They currently have a $14.00 price target on the stock. Deutsche Bank’s price objective indicates a potential upside of 65.09% from the company’s current price.

Shares of Verastem (NASDAQ:VSTM) traded up 1.89% on Friday, hitting $8.64. The stock had a trading volume of 324,991 shares. Verastem has a 1-year low of $7.10 and a 1-year high of $18.24. The stock has a 50-day moving average of $9.37 and a 200-day moving average of $11.0. The company’s market cap is $223.2 million.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.43) by $0.08. Analysts expect that Verastem will post $-2.06 EPS for the current fiscal year.

Separately, analysts at Oppenheimer initiated coverage on shares of Verastem in a research note on Monday. They set a “market perform” rating and a $8.99 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $19.14.

Verastem, Inc is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.